Rein Therapeutics Inc (RNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -62,883 | -15,732 | -27,329 | -26,164 | -21,157 |
| Depreciation Amortization | 37,063 | 151 | -39 | 361 | 154 |
| Income taxes - deferred | -1,554 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -279 | -4,982 | 510 | -386 | 116 |
| Other Working Capital | 3,966 | -5,381 | 420 | 242 | -1,280 |
| Other Operating Activity | 1,396 | 6,136 | 1,573 | 2,193 | 1,691 |
| Operating Cash Flow | $-22,291 | $-19,808 | $-24,865 | $-23,754 | $-20,476 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 42 | N/A | -91 | 203 |
| Net Acquisitions | N/A | -96 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | N/A | -21,850 | -73,577 | -10,034 |
| Sale Of Investment | N/A | 16,250 | 48,309 | 37,751 | 16,242 |
| Investing Cash Flow | $N/A | $16,196 | $26,459 | $-35,917 | $6,411 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 15,794 | N/A | N/A | 387 |
| Common Stock Issued | 17,818 | N/A | N/A | 55,657 | 15,413 |
| Financing Cash Flow | $17,818 | $15,794 | $N/A | $55,657 | $15,800 |
| Exchange Rate Effect | N/A | -63 | N/A | N/A | N/A |
| Beginning Cash Position | 17,338 | 5,219 | 3,625 | 7,639 | 5,904 |
| End Cash Position | 12,865 | 17,338 | 5,219 | 3,625 | 7,639 |
| Net Cash Flow | $-4,473 | $12,119 | $1,594 | $-4,014 | $1,735 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,291 | -19,808 | -24,865 | -23,754 | -20,476 |
| Capital Expenditure | N/A | N/A | N/A | -157 | -5 |
| Free Cash Flow | -22,291 | -19,808 | -24,865 | -23,911 | -20,481 |